Inventiva SA

11/03/2021 | Press release | Distributed by Public on 11/03/2021 14:01

Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021

Daix (France), Long Island City (New York, United States), November 3, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that it will host a webcast event focused on NASH with the participation of four Key Opinion Leaders (KOLs) on November 19, 2021 from The Liver Meeting™ 2021, organized by the American Association for the Study of Liver Diseases (AASLD).

Following an introduction from Frédéric Cren, Chairman, CEO and cofounder of Inventiva and Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, the event will consist of the presentation of five scientific abstracts presented at AASLD The Liver Meeting™ 2021, as well as four presentations focused on the latest news around the development of lanifibranor and various aspects related to NASH. As part of the program, there will be dedicated Q&A sessions.

Download PDF